Short traders are more bullish on shares of Catalyst Pharmaceuticals, Inc. recently if you evaluate the change in short interest. The firm realized a fall in short interest from August 31, 2017 to September 15, 2017 of -35.40%. Short shares fell from 6,532,907 to 4,220,460 over that timeframe. The short-interest ratio decreased to 5.0 and the percentage of shorted shares is 0.05% as of September 15.
Here are a few substantial investment firms who have updated their positions. Oxford Asset Management augmented its investment by buying 27,228 shares an increase of 46.2%. Oxford Asset Management currently owns 86,168 shares worth $238,000. The value of the position overall is up by 107.0%. As of the end of the quarter Boothbay Fund Management, LLC had acquired a total of 29,275 shares growing its stake by 73.7%. The value of the investment in Catalyst Pharmaceuticals, Inc. went from $97,000 to $190,000 a change of 95.9% quarter over quarter.
Candriam Luxembourg S.c.a. trimmed its position by shedding 40,000 shares a decrease of 6.7% as of 06/30/2017. Candriam Luxembourg S.c.a. claims 560,000 shares with a value of $1,546,000. The total value of its holdings increased 32.1%. As of quarter end Berson & Corrado Investment Advisors, LLC had sold 41,450 shares trimming its holdings by 30.4%. The value of the investment in (CPRX) decreased from $377,000 to $240,000 a change of $137,000 quarter to quarter.
The company is now down from yesterday’s close of 2.72. The stock last traded at $2.65 which is marginally over $2.60, the 50 day moving average and a bit higher than the 200 day moving average of $2.41. The 50 day moving average was up by +2.09% and the 200 day average moved up $0.24.
As of the last earnings report the EPS was $-0.20 and is expected to be $-0.23 for the current year with 84,554,000 shares now outstanding. Next quarter’s EPS is estimated at $-0.06 and the next full year EPS is anticipated to be $-0.25.
Catalyst Pharmaceuticals, Inc., formerly Catalyst Pharmaceutical Partners, Inc., launched on July 21, 2006, is a development-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115..